Profund Advisors LLC Makes New Investment in Stoke Therapeutics, Inc. $STOK

Profund Advisors LLC acquired a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 33,388 shares of the company’s stock, valued at approximately $1,060,000.

Other large investors have also modified their holdings of the company. Principal Financial Group Inc. acquired a new position in shares of Stoke Therapeutics in the third quarter worth about $1,062,000. Penserra Capital Management LLC acquired a new position in shares of Stoke Therapeutics in the third quarter worth about $3,539,000. Vanguard Group Inc. raised its position in shares of Stoke Therapeutics by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock worth $74,351,000 after purchasing an additional 217,616 shares during the last quarter. Baillie Gifford & Co. acquired a new position in shares of Stoke Therapeutics during the 4th quarter worth about $7,837,000. Finally, Hussman Strategic Advisors Inc. acquired a new position in shares of Stoke Therapeutics during the 4th quarter worth about $2,000,000.

Insider Activity at Stoke Therapeutics

In related news, Director Adrian R. Krainer sold 33,243 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total transaction of $1,321,076.82. Following the completion of the sale, the director owned 283,302 shares of the company’s stock, valued at approximately $11,258,421.48. This represents a 10.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Barry Ticho sold 1,461 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $29.99, for a total transaction of $43,815.39. Following the sale, the insider directly owned 40,702 shares of the company’s stock, valued at approximately $1,220,652.98. This represents a 3.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 69,699 shares of company stock worth $2,526,714 in the last 90 days. 9.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

STOK has been the subject of several research analyst reports. Wolfe Research initiated coverage on shares of Stoke Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price target for the company. Canaccord Genuity Group upped their price target on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Monday, May 11th. Chardan Capital restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 18th. Finally, Weiss Ratings downgraded shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Stoke Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $41.83.

Stoke Therapeutics Trading Down 2.1%

Shares of NASDAQ STOK opened at $29.67 on Friday. Stoke Therapeutics, Inc. has a 12-month low of $9.09 and a 12-month high of $40.22. The stock has a market cap of $1.85 billion, a PE ratio of -10.56 and a beta of 1.20. The company has a 50-day moving average of $33.36 and a 200 day moving average of $31.94.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The company had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.48 million. On average, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.